NCT07167329View on ClinicalTrials.gov

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

January 1, 2030

Conditions
Von Hippel LindauVon Hippel Lindau DiseaseVon Hippel Lindau-Deficient Clear Cell Renal Cell CarcinomaHemangioblastoma (HB) of the Central Nervous System (CNS)PNETRetinal Angiomatous ProliferationPheochromocytoma/ParagangliomaEndolymphatic Sac Tumor
Interventions
DRUG

Belzutifan

Patients with Von Hippel-Lindau Syndrome presenting with lesions or neoplasms requiring treatment with oral Belzutifan.

Trial Locations (1)

01509900

RECRUITING

AC Camargo Cancer Center, São Paulo

All Listed Sponsors
collaborator

AC Camargo Cancer Center

OTHER

lead

José Claudio Casali da Rocha

OTHER